You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Systematic review
No evidence for switching antidepressants in treatment-resistant depressed patients

https://doi.org/10.1136/ebm1083

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests MT has received consultancy fees, speakers fees and/or grants from: Adolar, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Lundbeck, MedAvante, Merck, Neuronetics, Novartis, Pharmaneuroboost, Otsuka, Pfizer, PGx Pharmaceuticals, Sepracror, Shire US, Supernus Pharmaceuticals, Takeda and Transcept.